SRRK:NSD-Scholar Rock Holding Corp (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 42.56

Change

+0.22 (+0.52)%

Market Cap

USD 3.79B

Volume

0.84M

Analyst Target

USD 28.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+0.84 (+0.19%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+0.94 (+0.14%)

USD 78.92B
ARGX argenx NV ADR

+6.65 (+1.03%)

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

-5.20 (-1.86%)

USD 30.22B
MRNA Moderna Inc

-4.22 (-9.39%)

USD 18.29B
RPRX Royalty Pharma Plc

+0.01 (+0.03%)

USD 18.12B
SMMT Summit Therapeutics PLC

-1.86 (-7.91%)

USD 17.52B
UTHR United Therapeutics Corporatio..

+1.90 (+0.51%)

USD 15.91B
INCY Incyte Corporation

+0.57 (+0.78%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.21 (+0.33%)

USD 12.74B

ETFs Containing SRRK

IBRN iShares Trust - iShares N.. 4.11 % 0.00 %

+0.05 (+0.20%)

USD 3.72M
PTH Invesco DWA Healthcare Mo.. 3.79 % 0.60 %

+0.17 (+0.20%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.53% 56% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.53% 56% F 36% F
Trailing 12 Months  
Capital Gain 205.09% 96% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 205.09% 96% N/A 97% N/A
Trailing 5 Years  
Capital Gain 246.30% 94% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 246.30% 94% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 32.62% 71% C- 81% B-
Dividend Return 32.62% 71% C- 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 101.28% 38% F 21% F
Risk Adjusted Return 32.21% 86% B+ 63% D
Market Capitalization 3.79B 94% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector